Not applicableApproved For MarketingNCT04504513
What this trial is testing
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
Who this might be right for
Myelosuppression AdultChemotherapeutic ToxicitySmall Cell Lung Cancer
G1 Therapeutics, Inc.